Oligonucleotides Cdmo Market: Market Size & Forecast 2026

Oligonucleotide CDMOs serve as contract manufacturing and development partners to pharmaceutical and biotechnology companies that lack the specialized infrastructure, chemistry expertise, and regulatory track record required for oligonucleotide drug production. Services span process development, analytical testing, clinical-scale manufacturing, and commercial-scale supply across DNA- and RNA-based modalities. The market has matured significantly from a niche service into a strategic industry segment, driven by the transition of oligonucleotide candidates from preclinical stages into late-stage clinical trials and onto the market.

• •Market valued at ~$2.52 billion in 2025; various projections cite figures between $6.7 billion (by 2029) and $18.4 billion (by 2034) depending on scope and methodology
• •Growth rate of ~19% CAGR reflects accelerating investment in RNA-based therapeutics and growing reliance on outsourced manufacturing
• •Landmark approvals including Spinraza (Biogen/Ionis), Leqvio (Novartis), and Amvuttra (Alnylam) have validated the category and spurred pipeline expansion

A robust and expanding clinical pipeline of oligonucleotide candidates is the single largest driver of CDMO demand, as dozens of ASOs, siRNAs, and aptamers advance through Phase II and Phase III trials requiring cGMP manufacturing capacity. The inherent chemical and manufacturing complexity of oligonucleotides, which demand specialized solid-phase synthesis, purification technologies, and stringent quality controls, makes in-house production impractical for most biopharma developers. Regulatory approvals across multiple therapeutic indications including rare genetic disorders, cardiovascular disease, and neurology have provided proof-of-concept validation, encouraging further investment.

• •Rising FDA and EMA approvals of oligonucleotide drugs have de-risked the modality and expanded the addressable therapeutic population
• •Precision medicine and personalized medicine trends are increasing demand for custom oligonucleotide synthesis at both research and clinical scales
• •Oligonucleotide manufacturing requires specialized infrastructure, chemistry expertise, and capital investment that most emerging biotechs cannot justify internally

The market is commonly segmented by service type, including process development, clinical manufacturing, and commercial manufacturing, with clinical services representing the largest and fastest-growing segment due to the expanding late-stage pipeline. Regional analysis consistently identifies North America as the dominant market, supported by a dense biopharma ecosystem, strong FDA activity, and leading CDMO infrastructure, while Europe and the Asia-Pacific region represent significant and growing demand centers. The Asia-Pacific market, led by China and India, is expanding rapidly as providers offer competitive pricing and growing regulatory harmonization.

• •Service type segmentation includes process development, clinical manufacturing, and commercial supply, with preclinical and clinical services as the dominant revenue contributors
• •North America holds the largest regional share, driven by the concentration of oligonucleotide developers, regulatory activity, and established CDMO facilities
• •Asia-Pacific is the fastest-growing region, with China and India emerging as key manufacturing hubs offering cost-competitive cGMP services

What are the recent trends and outlook?

The market is positioned for sustained long-term growth as the oligonucleotide pipeline deepens across cardiovascular, neurological, rare disease, and oncology indications, with CDMO capacity continuing to expand through new facility investments and strategic acquisitions. Emerging technologies such as next-generation conjugation chemistries, GalNAc and other targeted delivery systems, and improved synthesis platforms are raising the complexity and value of outsourced manufacturing services. Long-term projections anticipate the market will reach well into the double-digit billions by the early 2030s as approved products scale commercially and new modalities including circular RNAs and CRISPR-related oligonucleotides enter development.

• •Long-term market projections converge on a range between $6.7 billion and $18.4 billion by 2029-2034, depending on whether projections include adjacent peptide CDMO segments and emerging modalities
• •Delivery technologies such as GalNAc conjugates, lipid nanoparticles, and alternative targeting ligands are increasing manufacturing complexity and CDMO service scope
• •New oligonucleotide formats including circular RNAs, aptamer-siRNA chimeras, and CRISPR guide RNAs represent emerging demand drivers beyond currently approved modalities